Deprecated: The each() function is deprecated. This message will be suppressed on further calls in /home/zhenxiangba/zhenxiangba.com/public_html/phproxy-improved-master/index.php on line 456
NZ780753B2 - Antigen-binding proteins that activate the leptin receptor - Google Patents
[go: Go Back, main page]

NZ780753B2 - Antigen-binding proteins that activate the leptin receptor - Google Patents

Antigen-binding proteins that activate the leptin receptor

Info

Publication number
NZ780753B2
NZ780753B2 NZ780753A NZ78075316A NZ780753B2 NZ 780753 B2 NZ780753 B2 NZ 780753B2 NZ 780753 A NZ780753 A NZ 780753A NZ 78075316 A NZ78075316 A NZ 78075316A NZ 780753 B2 NZ780753 B2 NZ 780753B2
Authority
NZ
New Zealand
Prior art keywords
seq
nos
antibodies
antigen
lepr
Prior art date
Application number
NZ780753A
Other versions
NZ780753A (en
Inventor
Judith ALTAREJOS
Jesper Gromada
Panayiotis Stevis
Original Assignee
Regeneron Pharmaceuticals Inc
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals Inc filed Critical Regeneron Pharmaceuticals Inc
Publication of NZ780753A publication Critical patent/NZ780753A/en
Publication of NZ780753B2 publication Critical patent/NZ780753B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

The present invention provides antibodies and antigen-binding fragments of antibodies that bind to leptin receptor (LEPR), and methods of using the same. According to certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR and activate LEPR signaling. In other embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind to LEPR and enhance sensitization of LEPR to an antigen. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that bind LEPR in the presence and absence of leptin. In certain embodiments, the invention includes antibodies and antigen-binding fragments of antibodies that induce signaling in cells expressing LEPR mutants that otherwise exhibit defective or impaired signaling in the presence of leptin. The antibodies and antigen-binding fragments of the present invention are useful for the treatment of lipodystrophies and other diseases and disorders associated with or caused by leptin deficiency or leptin resistance.

Claims (2)

What is claimed is:
1. One or more polynucleotides encoding (a) the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) comprising HCDR1, HCDR2, and HCDR3 amino acid sequences, respectively, of: SEQ ID NOs:4, 6, and 8; SEQ ID NOs:20, 22, and 24; SEQ ID NOs:28, 30, and 32; SEQ ID NOs:36, 38, and 40; SEQ ID NOs:44, 46, and 48; SEQ ID NOs:52, 54, and 56; SEQ ID NOs:60, 62, and 64; SEQ ID NOs:68, 70, and 72; SEQ ID NOs:76, 78, 80; SEQ ID NOs:84, 86, and 88; SEQ ID NOs:100, 102, and 104; or SEQ ID NOs:108, 110, and 112, and (b) the light chain CDRs (LCDR1, LCDR2, and LCDR3) of a light chain variable region (LCVR) comprising an LCDR1, LCDR2, and LCDR3 amino acid sequences, respectively, of SEQ ID NOs:12, 14, and 16 or SEQ ID NOs:92, 94, and 96.
2. The one or more polynucleotides of claim 1 encoding the heavy and light chain CDRs of an HCVR/LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs:
NZ780753A 2016-10-11 Antigen-binding proteins that activate the leptin receptor NZ780753B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562240021P 2015-10-12 2015-10-12
US201662359757P 2016-07-08 2016-07-08
US201662375495P 2016-08-16 2016-08-16
US201662393143P 2016-09-12 2016-09-12
NZ741097A NZ741097B2 (en) 2016-10-11 Antigen-binding proteins that activate the leptin receptor

Publications (2)

Publication Number Publication Date
NZ780753A NZ780753A (en) 2025-06-27
NZ780753B2 true NZ780753B2 (en) 2025-09-30

Family

ID=

Similar Documents

Publication Publication Date Title
IL309975A (en) Anti-c5 antibodies and uses thereof
PE20200294A1 (en) ANTIBODIES THAT SPECIFICALLY BIND PD-1 AND METHODS OF USE
NZ600768A (en) Human antibodies to human angiopoietin-like protein 4
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
NZ628943A (en) Human antibodies to clostridium difficile toxins
IL273841B1 (en) Antibodies directed against CD137 and methods of use thereof
JP2017505125A5 (en)
PE20200011A1 (en) ANTI-PEPTIDE BETA AMYLOID N3pGlu ANTIBODIES AND THEIR USES
MX2019007848A (en) Anti-pd-1 antibodies and uses thereof.
PE20090161A1 (en) MONOCLONAL ANTIBODIES ANTI CXCL13
RU2010107175A (en) HUMAN ANTIBODIES TO HUMAN CD20 AND METHOD OF USE THEREOF
AR103713A1 (en) ANTIBODIES AGAINST TAU AND ITS USES
EA035160B9 (en) Anti-st2 antibodies and use thereof
NZ595011A (en) Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases
NZ608660A (en) Anti-cd48 antibodies and uses thereof
PE20180604A1 (en) PD-L1 ANTIBODIES (JOINING LINK 1 OF PROGRAMMED CELL DEATH 1 HUMAN)
JP2013542194A5 (en)
PE20081503A1 (en) UNION MEMBERS FOR IL-6
NZ598202A (en) High affinity human antibodies to human angiopoietin-2
NZ610734A (en) Human antibodies to the glucagon receptor
NZ609619A (en) Novel egfr-binding molecules and immunoconjugates thereof
PE20221337A1 (en) TREM2 ANTIBODIES AND THEIR USES
JP2023093753A5 (en)
JP2021500916A5 (en)
AR098663A1 (en) MULTIFUNCTIONAL ANTIBODIES THAT JOIN EGFR AND MET